- Oops!Something went wrong.Please try again later.
The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC).
Bavdegalutamide reduced prostate-specific antigen (PSA) levels greater than or equal to 50% (PSA50) in 46% of patients with tumors harboring AR T878X/H875Y mutations.
The Company plans to initiate a pivotal trial by year-end 2022.
Two confirmed partial responses were observed out of seven evaluable patients with AR T878X/H875Y tumor mutations.
PSA50 rate of 26% (five of 19) in evaluable patients in the subgroup defined as "less pretreated" (having received only one prior hormonal agent and no prior chemotherapy).
Most treatment-related adverse events (TRAEs) were mild to moderate, and there were no serious/life-threatening TRAEs in the 113 patients treated at the recommended 420 mg dose.
Price Action: ARVN shares were down 4.93% at $71.82 during the market session on the last check Tuesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.